PubMed Journals Articles About "Karus Therapeutics Ltd" - Page: 4 RSS

21:55 EDT 28th March 2020 | BioPortfolio

Karus Therapeutics Ltd PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Karus Therapeutics Ltd articles that have been published worldwide.

More Information about "Karus Therapeutics Ltd" on BioPortfolio

We have published hundreds of Karus Therapeutics Ltd news stories on BioPortfolio along with dozens of Karus Therapeutics Ltd Clinical Trials and PubMed Articles about Karus Therapeutics Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Karus Therapeutics Ltd Companies in our database. You can also find out about relevant Karus Therapeutics Ltd Drugs and Medications on this site too.

Showing "Karus Therapeutics" PubMed Articles 76–100 of 1,500+

Note: Zolgensma data manipulation.

Engineering Next-Generation Medicines: It's All About Delivery.

Editorial: the problem of supragastric belching needs to be heard.

In brief: Ezallor Sprinkle--a new formulation of rosuvastatin.

Leptotrichia Bacteremia After Chemotherapy for Hematologic Malignancy.

Influenza vaccine for 2019-2020.

Acetazolamide-Associated Hyperosmolar Hyperglycemic Nonketotic Syndrome.

Chest Pain Induced by Intravenous Nitroglycerin.

Corticosteroids in community-acquired pneumonia.

Darolutamide (Nubeqa) for prostate cancer.

Annovera - a new contraceptive vaginal ring.

Adjuvant Therapy With β-Adrenergic Blockers in Psychiatry.

Systemic Inflammatory Response Syndrome due to Nitrofurantoin Use.

Machine Learning for Cancer Drug Combination.

Istradefylline (Nourianz) for Parkinson's disease.

Decision Support Systems and Closed Loop.

Continuous and Intermittent Glucose Monitoring in 2019.

ATTD 2020 Abstract Author Index.

Transient Psychosis After Low-Dose Pregabalin Discontinuation.

Novel Targets to Treat Depression: Opioid-Based Therapeutics.

After participating in this activity, learners should be better able to:• Identify the effects of dysregulated opioid signalling in depression• Evaluate the use of opioid compounds and ketamine in patients with depression ABSTRACT: Major depressive disorder (MDD) remains one of the leading causes of disability and functional impairment worldwide. Current antidepressant therapeutics require weeks to months of treatment prior to the onset of clinical efficacy on depressed mood but remain ineffective in tr...

Does evidence support vitamin D treatment for multiple sclerosis?

Solriamfetol (Sunosi) for excessive daytime sleepiness.

In brief: Risk of pulmonary thromboembolism and death with tofacitinib.

Overcoming Regulatory Aversion to Novel Methods of Evidence Generation.

Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities.

Quick Search